A new study published in the European Journal of Nuclear Medicine and Molecular Imaging suggests that a hybrid imaging technique may finally bring quantitative rigor to this assessment. Researchers at Peking Union Medical College Hospital in Beijing prospectively enrolled 33 patients with thyroid-associated ophthalmopathy and scanned them on an integrated PET/MRI system using a radiotracer called 18F-NOTA-FAPI-04. Unlike conventional FDG, which tracks glucose metabolism in any active cell, FAPI tracers bind to fibroblast activation protein, a molecule displayed by activated fibroblasts and their inflammatory partners. Because thyroid eye disease is fundamentally a fibroinflammatory disorder of the orbital tissues, the tracer offers a way to visualize the cellular machinery driving the disease rather than its downstream anatomical consequences.

The technical logic of the study is worth unpacking. Each patient’s orbits were imaged simultaneously with PET, which quantifies molecular uptake, and with a battery of advanced MRI sequences that probe tissue microstructure. The MRI panel included T2 mapping, which reflects tissue water content and therefore edema; intravoxel incoherent motion diffusion imaging, which separates true water diffusion from blood flow within capillaries; and diffusion kurtosis imaging, which captures deviations from simple Gaussian diffusion and thus hints at tissue complexity. From these sequences the team extracted parametric maps of normalized T2 signal, the heterogeneity index alpha, the distributed diffusion coefficient, the diffusion coefficient, relative blood flow, mean diffusivity, and mean kurtosis. The goal was to see whether the molecular signal from PET and the microstructural signal from MRI tell the same story, and whether combining them outperforms either alone.

Participants were classified using the Clinical Activity Score, with eyes scoring three or higher considered active and those below three considered inactive. At the patient level, a person was labeled inactive only if both eyes were inactive. The researchers then extracted a rich set of quantitative features from each eye: PET metrics including maximum and mean standardized uptake values, metabolic tumor volume, and total lesion FAPI uptake, plus first-order histogram statistics such as mean, skewness, and kurtosis from each MRI parametric map. A support vector machine, a standard machine-learning classifier, was trained to distinguish active from inactive disease, and performance was evaluated with receiver operating characteristic analysis.

Reliability came first, and the numbers were reassuring. Interobserver and intraobserver agreement in delineating the orbital regions of interest was strong, with Dice similarity coefficients of 0.850, 0.880, and 0.901 for the different comparisons. Every quantitative PET and MRI parameter showed excellent reproducibility, with intraclass correlation coefficients above 0.907. In a field where subjective eyeballing of scans has long been the norm, this level of measurement stability matters: it means the features being fed into the classifier are not artifacts of who happened to draw the contours.

The correlation analysis produced one of the study’s most interesting nuances. At the patient level, where both eyes are averaged together, PET and MRI features correlated only weakly. But when each eye was analyzed as its own unit, the correlations strengthened considerably, particularly between PET uptake metrics and features derived from T2 mapping, the heterogeneity index, the diffusion coefficient, and mean diffusivity. This asymmetry makes biological sense. Thyroid eye disease is notoriously asymmetric, with one eye often far more inflamed than the other, and averaging across eyes dilutes the very signals that matter. The finding is a quiet argument for eye-level, rather than patient-level, imaging assessment in orbital disease.

The group comparisons confirmed that several quantitative features separate active from inactive disease. At the eye level, mean standardized uptake value, metabolic tumor volume, and total lesion FAPI uptake were all significantly higher in active eyes, while maximum standardized uptake value alone showed no significant difference, a reminder that peak values are often less informative than volume-weighted averages. On the MRI side, features from T2 mapping, the heterogeneity index, the diffusion coefficient, mean diffusivity, and mean kurtosis also differed significantly between active and inactive groups, consistent with the idea that active disease carries more edema and altered diffusion characteristics than fibrotic, quiescent tissue.

When it came to discriminating activity, the combined approach won. Among single PET parameters, mean standardized uptake value performed best at the patient level with an area under the curve of 0.759, while metabolic tumor volume led at the eye level with an AUC of 0.767. These are respectable but unremarkable figures, in the range of many clinical biomarkers. The combined PET/MRI model, however, pushed performance to an AUC of 0.844 at the patient level and 0.859 at the eye level. The improvement over either modality alone indicates that FAPI uptake and MRI-derived microstructural features carry complementary, not redundant, information about the state of the orbital tissues. In practical terms, the PET signal appears to capture the cellular fibroinflammatory process while the MRI parameters capture its tissue-level consequences, and the classifier benefits from having both.

The clinical implications are significant. Treatment for active thyroid eye disease, including high-dose glucocorticoids and newer targeted agents such as anti-IGF-1 receptor antibodies, works best early in the inflammatory phase and offers little once fibrosis has set in. Conversely, rehabilitative surgeries are best deferred until the disease is inactive. A quantitative imaging biomarker that reliably separates these phases could spare patients from ineffective treatment, reduce exposure to steroid side effects, and help time interventions more precisely. It could also serve as an objective endpoint in clinical trials, where the Clinical Activity Score’s known inter-observer variability has long complicated the interpretation of results. Prior studies have explored FDG-PET and multiparametric MRI separately for this purpose, but the FAPI tracer’s specificity for activated fibroblasts, combined with simultaneous MRI acquisition on a single scanner, represents a meaningful step forward in what the field calls molecular-radiological phenotyping.

Cautions remain, and the authors are candid about them. Thirty-three patients is a small cohort, and the classifier’s performance will need validation in larger, independent, and ideally multi-center populations before it can influence routine care. The Clinical Activity Score itself, used here as the reference standard, is an imperfect ground truth, which means the imaging model is being trained to reproduce a clinical judgment rather than to measure disease biology directly. The study was registered as a clinical trial and conducted under ethics approval at Peking Union Medical College Hospital, and the team notes that further validation is required. Still, the trajectory is clear: a single integrated scan that fuses molecular information about fibroblast activity with quantitative maps of tissue edema, perfusion, and diffusion could transform thyroid eye disease from a condition assessed by counting symptoms into one measured, monitored, and treated on the basis of what is actually happening inside the orbit. For a disease that can quietly steal sight, that kind of clarity cannot come soon enough.

Subject of Research: Quantitative assessment of disease activity in thyroid-associated ophthalmopathy using integrated 18F-NOTA-FAPI-04 PET/MRI

Article Title: Integrated 18F-NOTA-FAPI-04 PET/MRI for quantitative assessment of disease activity in thyroid-associated ophthalmopathy

Article References: Yang, X., Gan, L., Shi, X., Wu, M., Li, E., Zhang, Y., Hao, Z., Huang, Z., Xing, H., Liu, X., & Huo, L. (2026). Integrated 18F-NOTA-FAPI-04 PET/MRI for quantitative assessment of disease activity in thyroid-associated ophthalmopathy. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08157-x

Image Credits: AI Generated

DOI: 10.1007/s00259-026-08157-x

Keywords: thyroid-associated ophthalmopathy, thyroid eye disease, PET/MRI, 18F-NOTA-FAPI-04, fibroblast activation protein, Clinical Activity Score, multiparametric MRI, intravoxel incoherent motion, diffusion kurtosis imaging, radiomics, support vector machine, Graves orbitopathy

Neonatal encephalopathy, a condition characterized by disturbed neurological function in newborns, often stems from perinatal hypoxic-ischemic injury. Its unpredictable trajectory frequently leaves clinicians grappling with imprecise prognoses, making treatment decisions daunting. Standard MRI metrics, while invaluable, primarily provide averaged diffusion measurements that fail to capture the intricacies of brain tissue heterogeneity. Diffusion kurtosis imaging, by contrast, extends beyond these traditional limits by assessing the degree of non-Gaussian water diffusion, thus illuminating subtler microstructural alterations. These distinctions hold potential to unravel complex pathophysiological processes occurring in the vulnerable neonatal brain.

At the core of DKI’s promise lies its ability to quantify kurtosis parameters, which essentially describe the deviation of water diffusion from simple Gaussian behavior. This sensitivity to microenvironment complexity enables the detection of subtle changes in cellular organization, density, and integrity—particularly relevant in the context of neonatal brain injury characterized by heterogeneous involvement of gray and white matter. Importantly, this could permit earlier and more accurate identification of infants at risk for long-term neurodevelopmental impairments, potentially before conventional imaging signs become evident.

The study in question meticulously explores the application of DKI metrics in neonates with varying severities of encephalopathy, mapping diffusion kurtosis parameters across several brain regions integral to motor, sensory, and cognitive functions. By correlating these diffusion profiles with clinical outcomes, including neurodevelopmental milestones recorded months later, the research aims to establish robust biomarkers that transcend the temporal limitations of current evaluation paradigms. The results reveal a complex interplay between regional kurtosis abnormalities and clinical prognosis, highlighting both the promise and current boundaries of DKI.

One of the enlightening revelations from this research is how diffusion kurtosis measures in deep gray matter structures—such as the basal ganglia and thalamus—show remarkable correlation with motor outcome deficits. These regions are notoriously difficult to evaluate traditionally but are pivotal in neurodevelopmental prognostication. The study demonstrates that elevated kurtosis values, indicative of altered microstructural complexity, might reflect early cytotoxic edema or evolving gliosis, each bearing distinct clinical implications. This insight adds a layer of nuance that could ultimately guide therapeutic interventions more precisely.

However, while DKI introduces a groundbreaking dimension of microstructural insight, its integration into routine clinical practice faces significant obstacles. The complexity of acquisition protocols demands longer scan times, which is challenging in neonatal populations due to movement and physiological instability. Moreover, the computational algorithms required for kurtosis analysis necessitate advanced software and expertise not ubiquitously available in all neonatal neuroimaging units. These technical hurdles underscore a key limitation: without widespread technological and methodological standardization, the clinical applicability of DKI remains a hurdle.

In addition to technical challenges, biological interpretation of DKI parameters remains an evolving field demanding cautious scrutiny. Diffusion kurtosis reflects a convolution of multiple cellular phenomena, including changes in intracellular and extracellular compartments, myelination patterns, and axonal density variations. Disentangling which pathological processes correspond to specific kurtosis changes requires further correlative studies incorporating histopathology or additional biomarkers. Such insight is critical to avoid overinterpretation and to tailor clinical utility precisely.

This area of study also raises intriguing questions about the potential of DKI to monitor therapeutic responses. Hypothermia, the current standard of care for hypoxic-ischemic encephalopathy, has variable outcomes. The prospect that DKI could serve as a biomarker to assess ongoing brain microstructure during and after intervention opens exciting avenues for personalized medicine. Monitoring kurtosis changes longitudinally might reveal neuroplastic recovery or progressive injury, facilitating timely alterations in clinical management.

One cannot ignore the broader implications of refining neuroprognostication tools that can accurately assess the severity and trajectory of encephalopathy. Beyond clinical decision-making, this could profoundly affect counseling for families, resource allocation, and the design of clinical trials for novel neuroprotective agents. The promise of a neuroimaging marker that reliably bridges brain microstructure with functional outcomes could revolutionize neonatal neurology by transforming unpredictable prognoses into data-driven forecasts.

Despite these promising aspects, the authors emphasize that diffusion kurtosis imaging is not a panacea. Its current sensitivity and specificity, while superior to conventional diffusion imaging in some domains, do not yet completely resolve the heterogeneity inherent in neonatal encephalopathy outcomes. There remain cases where kurtosis measures produce ambiguous results, mandating multimodal approaches that integrate clinical, electrophysiological, and metabolic data for comprehensive evaluation. The authors advocate for a future where DKI complements rather than replaces existing diagnostic frameworks.

Technological advancements are anticipated to alleviate some issues related to DKI implementation. Developments in rapid acquisition sequences, motion correction algorithms, and artificial intelligence-driven image processing hold potential to streamline and democratize the use of kurtosis imaging. Such innovations could shorten imaging times, enhance resolution, and reduce interpretive subjectivity, making DKI feasible even in less specialized centers. These advances will be pivotal if diffusion kurtosis imaging is to transcend research settings and fulfill its promise in neonatal care.

Another emerging horizon involves integrating DKI with other advanced neuroimaging modalities, such as functional MRI and spectroscopy. Multimodal imaging has shown superior prognostic precision by providing complementary information on brain metabolism, connectivity, and structure. The synergistic use of these techniques could construct a multidimensional framework for assessing neonatal brain injury, surpassing the granularity offered by any single modality alone. The study by Lewis et al. hints at this integrative future by situating DKI within broader neuroimaging innovations.

While this research marks a decisive stride towards enhancing neuroprognostication in neonatal encephalopathy, it simultaneously highlights the importance of longitudinal studies involving larger cohorts. Validation across diverse populations and clinical settings is essential to establish normative kurtosis values and diagnostic thresholds, enabling robust translation into clinical practice. Additionally, harmonizing imaging protocols internationally will facilitate comparative studies and foster consensus on best practices for DKI application in neonatology.

Ethical considerations also emerge when implementing advanced prognostic technologies. The ability to predict neurological outcomes with increasing accuracy raises questions about decision-making in critical care, parental counseling, and potential biases in treatment allocation. Hence, alongside technological progress, frameworks ensuring compassionate communication and equitable care delivery must evolve in tandem. The nuanced prognostic data provided by DKI necessitate thoughtful clinical integration to truly benefit afflicted infants and their families.

In conclusion, diffusion kurtosis imaging stands at the nexus of neuroimaging innovation and neonatal clinical application. The work by Lewis, Kalish, and Cizmeci encapsulates an inspiring trajectory towards more precise, biologically grounded prognostication in the challenging landscape of neonatal encephalopathy. Although facing notable practical and interpretive limitations, DKI advances our ability to peer into the infant brain’s microarchitecture, promising transformative impacts on early diagnosis, treatment stratification, and ultimate neurodevelopmental outcomes. The journey from research to bedside application will demand continued interdisciplinary collaboration, technological refinement, and ethical vigilance but holds profound potential to change neonatal neurology forever.

Subject of Research: Neuroprognostication in neonatal encephalopathy using diffusion kurtosis imaging

Article Title: Advancing neuroprognostication in neonatal encephalopathy: promise and limitations of diffusion kurtosis imaging

Article References: Lewis, J.D., Kalish, B.T. & Cizmeci, M.N. Advancing neuroprognostication in neonatal encephalopathy: promise and limitations of diffusion kurtosis imaging. Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04714-6

Image Credits: AI Generated

DOI: 15 December 2025